VA opens 18-site trial of semaglutide as a treatment for alcohol use disorder
The CRAVE study will give more than 600 veterans weekly injections of the drug sold as Ozempic and Wegovy, or a placebo, for 24 weeks. Recruitment began July 28, and VA warns veterans not to try the drug on their own.
More than 400,000 veterans have an alcohol use disorder diagnosis, and the Department of Veterans Affairs began recruiting July 28 for a trial testing whether semaglutide, a diabetes and weight-loss drug, can help them drink less[1, 2].
VA announced the study July 30. Called Cessation or Reduction of Alcohol Consumption in Veterans, or CRAVE, it will enroll more than 600 veterans at 18 VA medical centers and compare weekly injections of semaglutide with a placebo over 24 weeks[1]. Semaglutide belongs to the class of drugs known as GLP-1 receptor agonists and is sold as Ozempic and Wegovy[1, 2]. Interest in the drugs as an addiction treatment has grown on the strength of studies of patient records, including one drawn from VA’s own health system, that found fewer substance use problems among people taking them[1, 3]. Those studies cannot show cause and effect. CRAVE is designed to.
The trial matters for a practical reason as well. The drugs are widely prescribed, and the Food and Drug Administration has approved semaglutide for Type 2 diabetes and chronic weight management, not for alcohol use disorder[2]. VA used its announcement to tell veterans not to try it on their own[1].
How the CRAVE trial works
Participants must be between 18 and 80 and have moderate or severe alcohol use disorder[1]. Each will be assigned to receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety follow-up[1]. Researchers will track changes in drinking, health and quality of life to judge whether the drug “offers a meaningful new treatment option,” VA said[1].
VA’s announcement does not give the dose participants will receive, a date for results or the cost of the study. It also does not say how many veterans each of the 18 sites is expected to enroll.
Secretary of Veterans Affairs Doug Collins framed the study as one the department is especially placed to run. “This clinical trial reflects medical research that VA is uniquely situated to launch, and is aimed directly at benefitting Veterans,” Collins said[1]. “By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery”[1].
VA estimates that alcohol use disorder affects nearly 11% of U.S. adults[1]. Among veterans, VA counts more than 400,000 with the diagnosis nationwide[1].
Why VA is testing a diabetes drug on drinking
The scientific case starts in the brain. Semaglutide has drawn interest because it may act on regions tied to how the body experiences rewards, according to VA[1]. Researchers at Washington University School of Medicine have increasingly studied whether GLP-1 drugs could also treat substance use disorders, Military Times reported[2].
VA pointed to an analysis published in March that found patients taking GLP-1 medications had lower rates of alcohol use disorder and other substance use disorders than similar patients taking other diabetes drugs[1]. That study drew on electronic health records of more than 600,000 VA patients with diabetes, according to FOX 5 DC, which cited The Associated Press[3]. Patients on drugs such as Ozempic and Mounjaro were less likely to develop addictions to alcohol, nicotine, cocaine, opioids and other substances than patients on a different class of drugs, and among people already addicted, the GLP-1 drugs were linked to lower risks of hospitalization, overdose and death[3].
The lead author, Dr. Ziyad Al-Aly, a chief researcher at the VA St. Louis Health Care System, told The Associated Press: “They’re actually working against the root cause of all these different addictions”[3]. The station noted the results suggest, but do not prove, a benefit[3].
VA itself drew the same line. In its announcement, the department said the use of GLP-1 drugs by people who already have substance use disorders has been associated with fewer emergency visits, hospitalizations and other adverse outcomes, and that “these findings highlight the need for a controlled clinical trial”[1].
What earlier semaglutide research on alcohol found
The closest test so far was small. A phase 2 trial published in JAMA Psychiatry in 2025 randomly assigned 48 adults with alcohol use disorder, none of them seeking treatment, to semaglutide or a placebo for nine weeks at a single U.S. academic medical center[4]. Enrollment ran from September 2022 to February 2024, and the dose stayed low, starting at 0.25 milligrams a week and reaching 1.0 milligram in the final week[4].
The results were mixed. In a laboratory session where participants could drink, those on semaglutide consumed less alcohol and reached lower peak breath alcohol levels than those on placebo[4]. Over the outpatient weeks, the drug reduced drinks per drinking day and weekly craving, and predicted greater reductions in heavy drinking over time[4]. It did not change average drinks per calendar day or the number of days participants drank[4]. Among participants who smoked, semaglutide also predicted greater reductions in cigarettes per day[4].
The authors called the findings “initial prospective evidence” that low-dose semaglutide “can reduce craving and some drinking outcomes,” and wrote that they justified “larger clinical trials”[4]. Of the 48 participants, 34 were women and the average age was about 40[4].
CRAVE is larger on every count that VA has made public: more than 12 times as many participants, 18 sites instead of one, and a treatment period nearly three times as long[1, 4]. It is also limited to veterans, a population the 2025 study did not single out[1, 4].
Where is VA enrolling veterans in the semaglutide trial?
VA listed these 18 medical centers[1]:
- Ann Arbor VA Health Care System, Ann Arbor, Michigan
- Charles George VA Medical Center, Asheville, North Carolina
- Durham VA Medical Center, Durham, North Carolina
- Edward Hines Jr. VA Hospital, Hines, Illinois
- George E. Wahlen VA Medical Center, Salt Lake City
- Joseph Maxwell Cleland Atlanta VA Medical Center, Decatur, Georgia
- Louis Stokes Cleveland VA Medical Center, Cleveland
- Michael E. DeBakey VA Medical Center, Houston
- Minneapolis VA Medical Center, Minneapolis
- Orlando VA Medical Center, Orlando, Florida
- Palo Alto VA Medical Center, Palo Alto, California
- Philadelphia VA Healthcare System, Philadelphia
- Portland VA Medical Center, Portland, Oregon
- Tibor Rubin VA Medical Center, Long Beach, California
- VA Greater Los Angeles Health Care System, Los Angeles
- VA North Texas Health Care System, Dallas
- VA Puget Sound Health Care System, Seattle
- William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin
California has four sites and North Carolina two. No site is listed in the Northeast north of Philadelphia, or in the Rocky Mountain states other than Utah[1].
Is semaglutide approved to treat alcohol use disorder?
No. Alcohol use disorder is not among the drug’s FDA-approved uses, which cover diabetes and weight management[2]. That is why VA’s announcement carried a warning. The department “strongly discourages self‑medicating or attempting to replace other AUD treatment options with GLP‑1 medications or any other unprescribed substances,” and said evidence-based treatments are already available at VA facilities[1].
The placebo arm means that a veteran who enrolls cannot count on receiving the drug[1]. The study is intended to settle whether semaglutide works for this use, which neither the record-based studies nor the 48-person trial could do[1, 3, 4].
If you’re affected
Veterans interested in joining CRAVE can contact their local VA medical center or search for the trial on ClinicalTrials.gov, according to VA[1]. The study is open to veterans ages 18 to 80 with moderate or severe alcohol use disorder at the 18 sites listed above, and recruitment began July 28[1].
Veterans who are already in treatment for alcohol use should talk with their VA provider before changing anything. VA says veterans “should always consult their health care providers before making any treatment decisions”[1].
Veterans who want help with drinking but are not near a study site, or do not want to join a trial, can ask their VA primary care or mental health team about the treatments VA already offers[1]. Whether semaglutide joins that list depends on what CRAVE finds after 24 weeks of injections at 18 hospitals.
Readers ask
- Can veterans get semaglutide from VA to treat alcohol use disorder?
- Only by enrolling in the CRAVE study, and even then half of participants receive a placebo[1]. The Food and Drug Administration has approved semaglutide for Type 2 diabetes and chronic weight management, not for alcohol use disorder[2].
- Who is eligible for the VA GLP-1 alcohol study?
- Veterans ages 18 to 80 with moderate or severe alcohol use disorder, at one of 18 participating VA medical centers[1]. Final eligibility is set by the study team at each site[1].
- How long does the CRAVE trial last for each participant?
- Participants get weekly injections for 24 weeks, followed by a safety follow-up[1]. Researchers will track drinking, health and quality of life over that period[1].
- How do I sign up for the VA semaglutide trial?
- VA says to contact your local VA medical center or search for the trial on ClinicalTrials.gov[1]. Recruitment opened July 28, 2026[1].
- Should I switch from my current alcohol treatment to a GLP-1 drug?
- No, not without your provider. VA “strongly discourages” self-medicating or replacing other treatment with GLP-1 drugs and says veterans should consult their health care providers first[1].
Sources
- VA launches trial of GLP-1 treatment for alcohol use disorder. Department of Veterans Affairs, VA News, July 30, 2026.
- VA launches trial to test GLP-1 medication for alcohol use disorder in veterans. Military Times, July 30, 2026.
- VA launches trial of GLP-1 drugs to treat alcohol use disorder in veterans. FOX 5 DC, July 31, 2026.
- Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial (Hendershot et al.). JAMA Psychiatry, April 1, 2025.
A note on sourcing
This report rests on VA’s July 30 announcement and on press coverage of it. VA did not say what dose of semaglutide participants will receive, when it expects results, or how much the study will cost, and the piece does not report those details. The March 2026 analysis of VA patient records is described as FOX 5 DC and The Associated Press reported it; the piece does not name the journal that published it. The 2025 JAMA Psychiatry trial was a small, single-site study of non-treatment-seeking adults and was not limited to veterans. The piece does not include comment from veterans service organizations or from the study’s investigators.
Filed underVA health care · alcohol use disorder · VA research · GLP-1 · clinical trials
Return to THE FRONT PAGE